Adenovirus formulations
AssigneeMerck & Co., Inc.
InventorsRobert K. Evans, David B. Volkin
Life of this patent
Estimating the term…
Abstract
The invention relates to viral formulations and related pharmaceutical products for use in gene therapy and/or vaccine applications. Especially preferred viral formulations disclosed herein are liquid adenovirus formulations, which show improved stability when stored in about the 2-8° C. range while also being compatible with parenteral administration. These formulations comprise a buffer, a sugar, a salt, a divalent cation, a non-ionic detergent, as well as a free radical scavenger and/or a chelating agent to inhibit free radical oxidation.
Claims45
A virus formulation comprising:
- a) a purified virus
- b) a buffer;
- c) a sugar;
- d) a salt;
- e) a divalent cation;
- and,
- f) a non-ionic detergent.
A virus formulation comprising:
- a) a purified virus
- b) a buffer;
- c) a sugar;
- d) a salt;
- e) a divalent cation;
- f) a non-ionic detergent;
- and,
- g) an inhibitor of free radical oxidation.
A virus formulation comprising at least one inhibitor of free radical oxidation selected from the group consisting of ethanol, EDTA, an EDTA/ethanol combination, triethanolamine, and sodium citrate.
A method of preserving a purified virus wherein a formulation is generated which comprises the purified virus, a buffer, a sugar, a salt, a divalent cation, and a non-ionic detergent.
A method of preserving a purified virus wherein a formulation is generated which comprises the purified virus, a buffer, a sugar, a salt, a divalent cation, non-ionic detergent, and an inhibitor of free radical oxidation.
Dependencies are inferred from the claim text.